LONDON (Dow Jones) – Pharmaceutical company Astrazeneca also plans to use its blood cancer drug Calquence to treat Covid-19. For this purpose, the company now wants to test it on critically ill patients with an overreaction of the immune system. The tests are expected to take place at multiple locations in the United States and Europe. The aim is to examine whether the therapy can reduce deaths and “the need for assisted ventilation” in Covid-19 patients.
A manager from Astrazeneca said this was the fastest start of a clinical trial in the company’s history.
Contact the author :email@example.com
DJG / DJN / bam / sha
(END) Dow Jones Newswires
April 14, 2020 09:01 ET (13:01 GMT)